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PURPOSE. To genetically characterize a subphenotype of geographic atrophy (GA) in AMD
associated with rapid progression and a diffuse-trickling appearance on fundus autofluores-
cence imaging.
METHODS. Patients from the Fundus Autofluorescence in Age-Related Macular Degeneration
Study were phenotyped for diffuse-trickling GA (dt-GA; n ¼ 44). DNA was analyzed for 10
known AMD-associated genetic variants. A genetic risk score (GRS) was calculated and
compared with patients with nondiffuse-trickling GA (ndt-GA; n ¼ 311) and individuals from
the 1000 genomes project (1000G; n ¼ 267). Given the phenotypic overlap between diffuse-
trickling and late-onset retinal degeneration (LORD), all C1QTNF5 exons and their exon/
intron boundaries were sequenced.
RESULTS. A statistically significant difference in allele frequencies between dt-GA and ndt-GA
were found for CFH:rs1061170 and CFH:rs800292 (Pcorrected ¼ 0.03). The ARMS2 variant
rs10490924 was significantly more frequent in dt-GA than in 1000G individuals (Pcorrected <
0.01). The GRS of dt-GA patients was in-between the score of the 1000G individuals and that
of patients with ndt-GA, significantly differing from both (Pcorrected <0.01). Sequencing of
C1QTNF5 revealed 28 unique variants although none showed a statistically significant
association with dt-GA when compared with 1000G individuals.
CONCLUSIONS. The dt-GA phenotype shows a remarkably different genetic risk profile from
other GA phenotypes secondary to AMD. Disease-associated C1QTNF5 mutations were not
identified. Together, these results suggest that the dt-GA phenotype is associated with a
genetic background substantially different from other GA phenotypes and underlines the
necessity to refine the clinical phenotyping, specifically when aiming for individualized
therapies in AMD.
Keywords: AMD, fundus autofluorescence imaging, diffuse-trickling phenotype, late-onset
retinal degeneration, C1QTNF5 gene, genetic risk factors
Geographic atrophy (GA) represents a morphologic end-stage in various retinal diseases including advanced AMD.
While choroidal neovascularization (CNV) is the most common
cause of severe visual loss in late stage AMD, approximately
20% of AMD-patients who are legally blind have lost central
vision due to GA.1–3
Geographic atrophy in AMD usually develops in the
presence of early disease alterations at the level of the retinal
pigment epithelium (RPE) and Bruch’s membrane with
funduscopically visible drusen and/or pigmentary alterations.4,5
Histologically, areas of GA are characterized by loss of RPE cells,
of outer layers of the neurosensory retina, and the choriocap-
illaris. The precise pathomechanisms of GA development
secondary to AMD are yet to be determined.
Age-related macular degeneration is a complex disease
influenced by both, genetic and environmental risk factors
with estimates of heritability varying from 45% to 71%.6 In a
recent effort, 52 independent signals representing 34 suscep-
tibility loci were identified to be associated with risk of late
stage AMD.7 Among those, several loci harbor genes of the
complement cascade, highlighting the crucial role of comple-
ment associated pathology in AMD.8 Additionally, signals were
found near genes of lipid and cholesterol metabolism as well as
extracellular matrix genes.9,10
To predict the genetic risk in complex diseases, testing of
single susceptibility variants is generally of limited value. In
contrast, genotyping and evaluation of a series of independent
disease-associated variants, a process also known as genetic
profiling, is more appropriate.11,12 This can be facilitated by a
genetic risk score (GRS) representing the sum of common risk
associated variants found in each individual, weighted by the
respective effect size (log-odds ratio) to account for differences
in risk modulation.
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Recent developments in retinal imaging technologies allow
for a more refined phenotyping of various retinal diseases and
have been shown useful to discriminate subphenotypes of
GA.13,14 In the context of the prospective natural history
Fundus Autofluorescence in Age-Related Macular Degeneration
(FAM) Study (ClinicalTrials.gov Identifier: NCT00393692) the
so-called diffuse-trickling GA (dt-GA) variant was identified by
comparative fundus autofluorescence imaging (FAF) and was
classified as a subtype of AMD.15,16 Several characteristic
features discriminate this distinct GA phenotype from other
AMD-related GA subtypes including (1) a significantly faster
disease progression (i.e., enlargement rates of atrophic areas),
(2) a lobular configuration of the atrophic patches, that exhibit
a grayish FAF signal, (3) a significantly thinner choroid, and (4)
a marked separation of the RPE/Bruch’s membrane complex in
spectral-domain optical coherence tomography (SD-OCT)
imaging, which was interpreted as excessive diffuse accumu-
lation of sub-RPE deposits (Fig. 1). Besides the morphologic
characteristics, patients with the dt-GA subtype differ from
patients with other AMD-related GA phenotypes by a
significantly younger age at first presentation and a higher
prevalence of cardiovascular comorbidity.15,17,18 These dis-
criminating findings have led to the hypothesis that a
differential pathogenesis is underlying the dt-GA phenotype
and have challenged the diagnosis of AMD.
In fact, there is phenotypic overlap with disease entities
other than AMD.19–21 Extensive macular atrophy with pseudo-
drusen-like appearance (EMAP) exhibits a very similar or even
the same phenotype and there is high resemblance with
characteristics described in age-related choroidal atrophy
(ARCA). Furthermore, there are striking similarities of the dt-
GA phenotype with the retinal degeneration described in
patients with late-onset retinal degeneration (LORD) (Fig. 1).
While no genetic causes have been identified for EMAP and
ARCA so far, autosomal-dominant inheritance is well estab-
lished for LORD (OMIM: 605670),22,23 which was found to be
associated with a single Ser163Arg missense mutation in the
globular C1q domain of the C1q and TNF-related protein 50
(C1QTNF5) gene.24 C1QTNF5 is a membrane-associated and
secretory protein in the RPE and ciliary body and the S163R
mutation of C1QTNF5 impairs its secretion and appears to
displays a significant reduction in implementing RPE cellular
adhesion.25–27 A key pathologic feature in LORD is a diffuse
thick extracellular sub-RPE deposit.26–28
In the present work, we aimed to determine the genetic
background of the dt-GA subphenotype and GA of other
phenotypes secondary to AMD. Due to phenotypic overlap
between dt-GA and LORD we additionally performed a
candidate gene approach by analyzing the C1QTNF5 gene.
METHODS
Ethics Statement
The study followed the tenets of the Declaration of Helsinki
and was approved by the local Ethics Review Board at the
University of Bonn, Bonn, Germany (ID: 082/04 and 197/12),
and the Department of Ophthalmology, University of
Wu¨rzburg, Wu¨rzburg, Germany (ID: 78/01). Informed written
consent was obtained from each patient after explanation of
the nature and possible consequences of the study.
Study Characteristics
Study characteristics are summarized in Table 1. Forty-four
patients with the dt-GA subphenotype were recruited as part
of the FAM study (in the public domain, www.clinicaltrials.gov:
NCT00393692), and its extension trial, the Directional Spread
in Geographic Atrophy (DSGA) study (NCT02051998). Both
have been described in detail elsewhere.16,17,29 Briefly, patients
needed to be above 50 years of age (55 years for DSGA) at the
time of inclusion and had to exhibit GA in at least one eye.
Clear ocular media that allowed for good-quality imaging had to
be present. Exclusion criteria included any history of retinal
surgery, laser photocoagulation, and radiation therapy or other
retinal disease in the study eye, including diabetic retinopathy.
Furthermore, 311 patients with GA but without the dt-GA
subtype were recruited in Wu¨rzburg11,30 and Bonn, equally as
part of the FAM study.16,29 Blood samples were taken from each
patient after informed consent was given.31 Additionally, we
included data from a total of 267 European subjects (Utah
Residents with Northern and Western European Ancestry
[CEU], British in England and Scotland [GBR], and Finnish in
Finland [FIN]) from the 1000 Genomes project (1000G;
Release 20110521, in the public domain, http://www.
1000genomes.org, accessed May 2, 2012).
Definition of GA due to AMD
Geographic atrophy was defined funduscopically as one or
more well-defined, usually more or less circular patches of
partial or complete depigmentation of the RPE, typically with
visualization of underlying large choroidal blood vessels.32,33 In
the FAM and DSGA-studies, GA due to AMD was further
defined as sharply demarcated lesions with clearly reduced
fundus autofluorescence (FAF) signal of an extend of greater
than or equal to 0.05 mm2 (approximately 178 lm in diameter)
that is not caused by masking effects of exudative retinal
changes (e.g., bleeding, exudation, fibrotic scar). Additionally,
the affected eye should have funduscopically visible soft
drusen and/or retinal pigment abnormalities consistent with
AMD.34
Definition of the dt-GA Phenotype
Phenotyping of GA was described in detail elsewhere.16,18 In
brief, the previously introduced classification of GA based on
abnormal FAF patterns,16 was used to identify the specific FAF
phenotype of each eye by two independent graders (MF, SSV)
and a third reader (FGH) in case of discrepancy.
The dt-GA phenotype was characterized in FAF images by
coalescent lobular atrophic lesions with an atrophic area
appearing rather grayish compared with the dark black
appearance of outer retinal atrophy seen in other GA subtypes.
Adjacent to atrophic patches, the FAF signal is markedly
enhanced with a diffuse trickling FAF signal toward the
periphery. Funduscopically, eyes with the FAF pattern charac-
teristic of dt-GA exhibit dense granular hyperpigmentation in
the central macula and the border areas of the atrophic lesions
appear hyperpigmented. Furthermore, adjacent to the atrophic
lesions, there are small yellowish spots. Reticular pseudodru-
sen are present, whereas soft drusen are rather infrequent in
this phenotype.15 Spectral-domain OCT imaging shows an
obvious separation of the RPE/Bruch’s membrane complex
(Fig. 1).15,16 If there was suspicion of exudative AMD based on
funduscopy (SD-OCT or FAF-imaging), fluorescein angiography
TABLE 1. Study Characteristics
dt-GA 1000G EUR ndt-GA
Number of individuals 44 267 311
Mean GRS (SD) 0.82 (1.69) 0.00 (1.36) 1.63 (1.34)
Mean age (SD) 67.20 (11.28) NA 78.76 (6.57)
Fraction of males, % 36.36 NA 34.49
To Characterize a Subphenotype of GA in AMD IOVS j May 2016 j Vol. 57 j No. 6 j 2464
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/935270/ on 01/30/2017
FIGURE 1. Fundus autofluorescence imaging and OCT imaging of eyes classified as dt-GA. There is variable extent of degeneration and variability in
age of patients ([A] 69-year-old male, [B] 71-year-old male, [C] 50-year-old female, and [D] 58-year-old female). Common findings are coalescent
lobular atrophic lesions with an atrophic area appearing grayish on FAF imaging. Optical coherence tomography imaging reveals a thin choroid and
a marked separation of the RPE/Bruch’s membrane complex. Eyes classified with dt-GA may phenotypically overlap with ARCA, EMAP, and LORD.
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was performed. Eyes were excluded from the analysis if a
neovascular phenotype was verified.
Genotyping and GRS
Genotyping was performed as described previously.11,30
Briefly, genomic DNA was extracted from peripheral blood
leukocytes by established methods. Genotyping was per-
formed by TaqMan SNP genotyping (Applied Biosystems,
Foster City, CA, USA) or by PCR followed by restriction
enzyme digestion (New England Biolabs, Ipswich, MA, USA)
and subsequent restriction fragment length analysis (RFLP).
The resulting genotypes were coded as the number of AMD
risk increasing alleles (0, 1, or 2), that is alleles, which are more
frequent in cases than in controls (Table 2).11 From these
variants, we computed the GRS according to Grassmann et
al.11 by including the weights obtained from the parsimonious
model based on 10 single nucleotide polymorphisms (SNPs;
Table 2). We only genotyped variants of the parsimonious 10
SNP model because it exhibited comparable classification
accuracy as the 13 SNP model proposed by Grassmann et al.11
Furthermore, recent studies showed that additional inclusion
of novel AMD-associated risk variants in such risk models
contributes only marginally to classification accuracy and
explained heritability.7 We subtracted 9.05 from all GRS values
to center the distribution on zero for the 1000G samples.
In addition, we estimated the variance explained by the 10
common variants on disease risk according to the liability
threshold model.35 We estimated the individual variance
explained for each variant and calculated the sum of those
measures to calculate the full variance explained. Because the
estimation of the explained variance is largely dependent on
the disease prevalence or the life time risk for the disease, we
assumed a lifetime disease risk for both diseases of 5%. This
allowed us to compare the explained variance for both
diseases.
Sequencing of the C1QTNF5 Gene and Data
Analysis
To minimize a potential bias by faulty inclusion of patients with
autosomal dominant LORD, we sequenced the coding position
c.489 (p.Asn131) in all patients and verified bi-allelic presence
of the wild type allele (C). Patients with the LORD associated
mutation (C1QTNF5:c.489C > G) were excluded from further
analysis (one case). To assess if other, possibly less severe,
mutations in the LORD-associated gene could be causative for
the dt-GA phenotype we amplified the 15 exons of C1QTNF5
(RefSeq: NM_015645.4) and their immediate flanking intronic
sequences. PCR fragments were generated for each exon
(Supplementary Table S1). The PCR fragments of each patient
were pooled equimolar and processed using the Ion Xpress
Plus Fragment Library kit (Life Technologies, Carlsbad, CA,
USA) according to the manufacturer’s protocol. We used the
Ion Xpress Barcode Adapters 1-96 to allow for multiplexing of
DNA libraries from different individuals. The resulting DNA
libraries were purified with AMPure beads (Beckman Coulter,
Brea, CA, USA), and their concentrations and sizes were
determined on an Agilent BioAnalyzer DNA high-sensitivity
Chip (Agilent Technologies, Santa Clara, CA, USA). Between 20
and 24 libraries were simultaneously sequenced by emulsion
PCR. Enrichment of cDNA-conjugated particles with the Ion
OneTouch 400 Template Kit v2 DL (Life Technologies) was
done according to the manufacturer’s protocol. The final
particles were loaded on an Ion 316 chip and sequenced with a
Personal Genome Machine (Ion Torrent) with 400-bp read
length (Life Technologies).
Reads were aligned to the C1QTNF5 reference sequence
(NM_015645.4) using the CLC Genomics Workbench (Qiagen,
Venlo, The Netherlands) and standard settings. To assure
sufficient power to detect heterozygous variants, the minimum
coverage threshold of an exonic base was set to 20 reads.
Fragments failing this threshold were resequenced with the
classical Sanger sequencing chain termination method. Variants
were called with the Probabilistic Variant Caller in CLC with
standard settings. A genotype was coded as the number of
minor alleles at a given variant (0, 1, or 2) for each identified
variant. To compare allele frequencies with a larger reference
sample, we extracted the genotypes of all identified variants for
267 EUR samples in 1000G (Interim Release 2011/05/21) and
coded the genotype according to the number of minor alleles.
Statistical Analyses and Visualization
We computed means and 95% confidence intervals (CIs) of the
GRS in different groups and used the ggplot function from the
ggplot236 package in R37 to draw jitterplots. The Student’s t-
test was used as implemented in R to evaluate differences in
the GRS between groups. Additionally, univariate logistic
regression was applied as implemented in R to evaluate the
association of single variants with dt-GA. Furthermore, we used
a Sequencing Kernel Association Test (SKAT) as implemented
in the package ‘SKAT’ in R to assess the overall burden of rare
and common variants on disease risk.38,39 The obtained raw P
values were adjusted by a conservative Bonferroni correction
TABLE 2. Frequency of Genetic Risk Variants in the Cohorts Investigated
dt-GA vs. ndt-GA dt-GA vs. 1000G EUR Frequency in
Odds
Ratio 95% CI
Raw P
Value
Corrected
P Value
Odds
Ratio 95% CI
Raw P
Value
Corrected
P Value dt-GA ndt-GA
1000G
EUR
APOE_rs429358 0.777 0.395–1.647 0.48 1 1.37 0.722–2.84 0.36 1 0.88 0.90 0.84
APOE_rs7412 1.45 0.75–2.654 0.25 1 2.413 1.218–4.639 0.01 0.09 0.16 0.12 0.07
ARMS2_rs10490924 0.876 0.566–1.337 0.55 1 2.357 1.43–3.916 0.001 0.01 0.39 0.42 0.22
C3_rs2230199 0.882 0.52–1.443 0.63 1 1.406 0.817–2.36 0.20 1 0.25 0.27 0.19
CFB_rs4151667 0.367 0.119–1.372 0.10 1 1.073 0.409–3.682 0.90 1 0.95 0.98 0.95
CFB_rs438999 0.342 0.149–0.843 0.01 0.14 0.923 0.446–2.156 0.84 1 0.91 0.97 0.92
CFH_rs1061170 0.503 0.315–0.795 0.003 0.03 1.52 0.965–2.407 0.07 0.72 0.50 0.66 0.40
CFH_rs6677604 0.545 0.305–1.011 0.04 0.45 0.815 0.468–1.49 0.48 1 0.82 0.89 0.85
CFH_rs800292 0.394 0.216–0.736 0.003 0.03 1.641 0.947–3.015 0.09 1 0.82 0.92 0.73
PLA2G12A_rs2285714 0.901 0.55–1.465 0.68 1 0.979 0.601–1.581 0.93 1 0.41 0.43 0.41
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by multiplying the P values with the number of (independent)
tests performed.
RESULTS
Genetic Risk of AMD in dt-GA Patients
To evaluate the genetic risk, we genotyped 10 known AMD
associated genetic variants in 44 dt-GA patients and 311
patients with ndt-GA. Additionally, we extracted the genotypes
for the 10 variants from 267 European individuals as given in
the 1000G (Table 2). We found a statistically significant
difference in the allele frequencies between dt-GA and ndt-
GA for CFH_rs1061170 (PCorrected¼ 0.035) and CFH_rs800292
(PCorrected ¼ 0.026) after adjustment for multiple testing.
Strikingly, only a single variant (APOE_rs7412) had a higher
frequency in dt-GA patients than in ndt-GA patients. Converse-
ly, we performed a similar analysis and compared dt-GA cases
with 1000G controls and found a nominally significant
association of two SNPs, ARMS2_rs10490924 and
APOE_rs7412 with disease. After adjustment for multiple
testing, only ARMS2_rs10490924 remained statistically signif-
icant (PCorrected ¼ 0.008).
To summarize the genetic risk, we computed the GRS11 for
the 1000G European individuals, for dt-GA patients and for
patients with ndt-GA and found mean GRS values of 0.00 (95%
CI: 0.16 to 0.16), 0.82 (95% CI: 0.32–1.32), and 1.63 (1.48–
1.78), respectively (Fig. 2). The mean GRS in dt-GA patients
was significantly lower than the mean GRS of ndt-GA patients
(PCorrected ¼ 0.01) but also significantly higher than the mean
GRS of control subjects (PCorrected ¼ 0.01). As expected, the
mean GRS for ndt-GA patients was significantly higher than the
GRS of control subjects (PCorrected < 13 1016). Because two
variants in the CFH gene were significantly different between
dt-GA and ndt-GA, we recalculated a GRS based on eight
variants (excluding CFH_rs1061170 and CFH_rs800292). We
found a nominally significant difference (P ¼ 0.049) between
the risk scores of dt-GA (mean: 0.53, 95% CI: 0.16–0.90) and
FIGURE 2. Genetic risk score distribution in cases and controls. The GRS was calculated according to the parsimonious model based on 10 variants
proposed in Grassmann et al.11 and centered on zero for control individuals. Each point represents one individual. We included 267 European
individuals from 1000G, 44 patients with dt-GA, and 311 patients with ndt-GA. Horizontal bars represent 95% confidence intervals for each mean.
Significant differences between means are indicated with an asterisk: *PCorrected < 0.01, ***PCorrected < 0.001.
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ndt-GA patients (mean: 0.94, 95% CI: 0.81–1.06), suggesting
that the observed GRS differences are due to the combined
effect of the individual variants.
Next, we estimated the variance explained by the 10
variants on disease risk in a liability threshold model40,41 using
the odds ratios obtained from comparing dt-GA and ndt-GA
cases to 1000G controls. Assuming a life time risk for ndt-GA
and dt-GA of 5%, we estimate the variance explained by those
10 variants for ndt-GA to be 43.4% and 14.5% for dt-GA,
indicating that other variants or environmental factors are
responsible for dt-GA risk.
Next Generation Sequencing of the C1QTNF5 Gene
and Association Testing
We sequenced the 15 exons and immediate flanking intronic
regions of C1QTNF5 and obtained on average 135,984 (SD 6
85,610) reads per individual/library. The average read length
was 182 bp (SD 6 51 bp) and the average coverage was 6541
(SD 6 5634) reads. In total, we found 28 unique variants in the
C1QTNF5 gene in 44 dt-GA patients. We compared the
frequencies of these variants with the frequencies observed
in the 1000G samples (Table 3). We fitted univariate logistic
regression models for each variant and found three variants
with nominally significant association with dt-GA. After
adjustment for multiple testing none of the variants remained
statistically significant.
To test whether the dt-GA phenotype could result from
distinct mutations within the C1QTNF5 gene, we compared
the total frequency of variants in the gene between dt-GA
individuals and the 1000G samples. We found a total of 182
variants in the dt-GA group and 1.254 variants in the group of
1000G individuals. This corresponds to an average of 4.14 (SD
61.77) and 4.70 (SD 61.89) variants per person, respectively,
and is not significantly different in the two groups (P > 0.05).
To assess the overall burden of genetic variation in the
C1QTNF5 gene in dt-GA risk, we analyzed all identified
variants in a SKAT by comparing the genotypes of dt-GA
patients with the genotypes obtained from the 1000G in the
C1QTNF5 gene. We found no statistically significant different
genetic burden of variants in C1QTNF5 (P > 0.05).
TABLE 3. Statistical Analysis of C1QTNF5 Variants Ordered by Ascending P Values
Variant
(hg19 position) rs–ID
Major
Allele
Minor
Allele
Effect of Variant
(on C1QTNF5)
Odds
Ratio 95% CI
Raw P
Value
Corrected
P Value
Minor allele
Frequency in
dt–GA
1000G
EUR
chr11:119211409 rs185696769 G C 50 UTR variant 25.900 2.606–396.8 0.006 0.175 0.023 0.002
chr11:119210380 rs146971652 C A Missense variant
(p.N131K)
25.230 1.941–3536 0.013 0.357 0.023 0
chr11:119215046 rs35885438 G A 50 UTR variant 0.237 0.026–0.915 0.034 0.957 0.011 0.079
chr11:119217311 rs883245 G A 50 UTR variant 0.645 0.391–1.048 0.077 1 0.409 0.502
chr11:119210884 – G A Intron variant
(þ9)
10.680 0.556–1574 0.113 1 0.011 0
chr11:119216231 rs2510143 T C 50 UTR variant 0.400 0.078–1.300 0.139 1 0.023 0.058
chr11:119216832 rs138913508 T C 50 UTR variant 6.556 0.330–979.8 0.216 1 0.011 0
chr11:119217254 rs883247 C T 50 UTR variant 0.758 0.451–1.251 0.28 1 0.375 0.431
chr11:119212363 rs138370910 G A 50 UTR variant 2.069 0.327–8.619 0.353 1 0.011 0.007
chr11:119209979 rs9640 A T 50 UTR variant 0.735 0.353–1.414 0.369 1 0.125 0.165
chr11:119213441 rs142533439 C T Intron variant
(4)
4.876 0.033–97.73 0.408 1 0 0.002
chr11:119210582 rs141429422 G A Intron variant
(24)
4.121 0.028–81.37 0.452 1 0 0.002
chr11:119216539 rs142584359 G A 50 UTR variant 3.747 0.025–73.45 0.478 1 0 0.002
chr11:119216169 rs141474039 C T 50 UTR variant 2.889 0.020–55.74 0.558 1 0 0.002
chr11:119214525 rs145719998 C A 50 UTR variant 2.340 0.016–44.80 0.631 1 0 0.002
chr11:119215007 rs185451482 A G Intron variant
(þ19)
2.035 0.014–28.25 0.678 1 0 0.004
chr11:119212213 rs184075096 G A 50 UTR variant 2.056 0.014–39.25 0.68 1 0 0.002
chr11:119216504 rs3814762 G A 50 UTR variant 0.903 0.543–1.468 0.685 1 0.307 0.326
chr11:119217288 rs883246 G A 50 UTR variant 0.609 0.005–5.515 0.721 1 0 0.013
chr11:119216279 rs36015759 C T 50 UTR variant 1.094 0.646–1.797 0.73 1 0.25 0.232
chr11:119216142 rs150902999 G T 50 UTR variant 1.225 0.115–6.741 0.839 1 0.011 0.011
chr11:119216274 rs200251814 G A 50 UTR variant 1.411 0.010–26.95 0.839 1 0 0.002
chr11:119213303 rs11217241 G A Intron variant
(þ3)
0.950 0.360–2.151 0.909 1 0.068 0.082
chr11:119210583 rs1135258 C A Intron variant
(25)
1.026 0.640–1.629 0.914 1 0.398 0.401
chr11:119217098 rs143351376 – TAC Intron variant
(16)
0.887 0.007–9.500 0.936 1 0 0.006
chr11:119217267 rs79836575 C T 50 UTR variant 0.887 0.007–9.500 0.936 1 0 0.006
chr11:119217280 rs139821533 G A 50 UTR variant 1.111 0.008–14.12 0.947 1 0 0.004
chr11:119216121 rs189840088 G A Intron variant (þ9) 1.046 0.008–11.07 0.976 1 0 0.007
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DISCUSSION
Here, we demonstrate that the dt-GA phenotype in late stage
AMD shows remarkable genetic differences from other FAF-
defined GA phenotypes. In addition, despite clinical similarities
between dt-GA and autosomal dominant LORD such as
excessive accumulation of hyperreflective material between
the RPE and Bruch’s membrane,15,21,42 no disease-associated
variants were detected in the LORD-associated C1QTNF5 gene.
From 10 prominent variants known to be strongly
associated with AMD risk, two of these, namely
CFH_rs1061170 and CFH_rs800292, revealed a statistically
significant difference in their allele frequencies between dt-GA
and ndt-GA. Furthermore, there was a single variant,
ARMS2_rs10490924, significantly associated with dt-GA when
comparing the frequency with 1000G individuals. Calculating a
GRS as previously described11 revealed a genetic risk profile of
dt-GA individuals significantly different from both, ndt-GA and
1000G individuals. With a GRS of 0.88 the genetic risk of dt-GA
was in-between that of 1000G and ndt-GA individuals.
Together, these findings suggest that genetic factors, which
may act in dt-GA are likely distinct from those responsible for
other phenotypes of GA secondary to AMD, especially because
those known factors only explain a small proportion of the
observed disease risk variance in dt-GA. These findings are in
line with recent findings, which provide evidence for
substantial clinical differences between dt-GA and ndt-
GA.15,16,18,43
The question arises whether variant ARMS2_rs10490924,
previously reported to significantly influence the progression
rate of GA lesions,33 could account for the faster GA growth in
dt-GA versus ndt-GA patients.15,17,18 Our data show, however,
that the frequency of the ARMS2_rs10490924 variant in dt-GA
patients is similar to the frequency in ndt-GA patients. This is
also true for the C3_rs2230199 variant, also known to be a risk
factor for GA lesion growth.33 These findings suggest that the
two variants associated with disease progression likely have no
role in the differences in lesion growth rate between dt-GA and
ndt-GA patients. Other so far unknown factors, genetic or
environmental, appear to play a role in the different
pathologies of DT-GA and NDT-GA.
The molecular analysis of the C1QTNF5 gene in DT-GA
patients was stimulated by the phenotypic overlap of DT-GA
with the retinal degeneration in patients diagnosed with LORD.
Most strikingly, the two disease pathologies share an excessive
accumulation of hyperreflective material between the RPE and
Bruch’s membrane as visualized by SD-OCT imaging.15,21,42
Nevertheless, genetic variants in C1QTNF5 were not signifi-
cantly associated with DT-GA when comparing with 1000G
individuals. To test for statistical power in our rather small
group of dt-GA patients, we conducted a post hoc power
analysis. Assuming there is a strong contribution to dt-GA risk
(odds ratio > 2.0) from one of the six common variants
(frequency >10% in 1000G individuals) in the transcribed
region of C1QTNF5, statistical power would be greater than
92% to find such an association with a P value smaller than
0.05. Alternatively, the combination of rare variants may
contribute to the disease risk jointly and lead to the
development of dt-GA. The present study, however, is
underpowered to investigate the latter possibility. Neverthe-
less, the C1QTNF5 protein and/or related proteins still attract
attention as candidates involved in the pathomechanism of dt-
GA, specifically as known AMD risk variants explain only a
small percentage of the variance of disease risk observed in DT-
GA patients.
A phenotypic overlap of two diseases may not necessarily
reflect a shared etiology but may be expression of a common
final pathway of different pathogeneses. Therefore, dt-GA,
LORD, EMAP, and ARCA may be unrelated diseases with a
similar unspecific end-stage phenotype. On the other hand, it
cannot be excluded that these diseases share a common
etiology with slightly differing end-stage manifestation. It is
noteworthy that patients who were classified to exhibit the dt-
GA phenotype show variable extend of degeneration and a
relatively high variability in age of onset. Therefore, the diffuse-
trickling phenotype may comprise patients with EMAP, ARCA,
and LORD. Indeed, one diffuse-trickling patient had been
excluded from the current analysis because of detection of the
LORD associated mutation C1QTNF5:c.489C > G.
Whether the diffuse-trickling phenotype can be classified as
AMD remains debatable. There are distinct characteristics that
discriminate the diffuse-trickling phenotype from typical AMD.
Here, we additionally demonstrate that dt-GA genetically differs
from other GA subtypes secondary to AMD. Together, these
findings strongly suggest that differential pathogenetic path-
ways are operative in distinct clinical phenotypes of GA, at
least between dt-GA and ndt-GA. This underscores the
importance of refined phenotyping particularly in the context
of designing interventional clinical trials for AMD targeting
specific pathways.
It is anticipated that with the ongoing development of
retinal imaging techniques, further subtypes of AMD will be
identified with differential pathogeneses when compared with
typical AMD. The concept where AMD represents a disease
spectrum rather than a homogenous entity appears appeal-
ing.44
To the best of our knowledge, this study demonstrates for
the first time a difference in the genetic profile between dt-GA
and other GA subtypes due to AMD. The candidate gene
approach examining the C1QTNF5 gene as an excellent
candidate gene due to phenotypic overlaps in disease
pathology failed to further elucidate the genetic background
of dt-GA. Further approaches to identify the true genetic cause
of dt-GA will include refined clinical phenotyping and possibly
further analysis of C1QTNF5 and related genes.
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